MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers

Head and Neck Cancer Clinical Trial

Official title:

Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02989064
• Other study ID #: ADP-0022-004
• Status: Completed
• Phase: Phase 1
• Start date: October 2016
• Est. completion date: June 4, 2020

Study information

• Verified date: May 2020
• Source: Adaptimmune
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This Phase 1 study is designed as a cell dose escalation trial in HLA-A*02:01 and HLA-A*02:06 subjects with MAGE-A10 positive urothelial, melanoma or head and neck tumors. The study will enroll subjects between the ages of 18 and 75 using a modified 3+3 cell dose escalation design, to evaluate dose limiting toxicities and determine the target cell dose range. Following the dose escalation phase, additional subjects will be enrolled at the target cell dose range to further characterize safety and the effects at this cell dose.

The study will take the subject's T cells, which are a natural type of immune cell in the blood, and send them to a laboratory to be modified. The changed T cells used in this study will be the subject's own T cells that have been genetically changed with the aim of attacking and destroying cancer cells. When the MAGE-A10ᶜ⁷⁹⁶T cells are available, subjects will undergo lymphodepleting chemotherapy with cyclophosphamide and fludarabine, followed by T cell infusion. The purpose of this study is to test the safety of genetically changed T cells and find out what effects, if any, they have in subjects with urothelial, melanoma or head and neck cancer.

Subjects will be seen frequently by the Study Physician after receiving their T cells for the next 6 months. After that, subjects will be seen every 3, 6, or 12 months according to the Schedule of Procedures. All subjects completing or withdrawing from the interventional portion of the study will enter a long term follow-up phase for observation of delayed adverse events and overall survival for 15 years post-infusion.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: June 4, 2020
• Est. primary completion date: December 18, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Subject is =18 to =75 years of age at the time of signing the study informed consent.

2. Subject has histologically confirmed diagnosis of any one of the following cancers:

(A) urothelial cancer (transitional cell cancer of the bladder, ureter or renal pelvis), (B) melanoma, or (C) squamous cell carcinoma of the head and neck.

3. Subject is HLA-A*02:01 and/or HLA-A*02:06 positive.

4. Subject has measurable disease according to RECIST v1.1 criteria prior to lymphodepletion

5. Subject meets disease-specific requirements per protocol

6. Subject has anticipated life expectancy > 6 months prior to leukapheresis and >3 months prior to lymphodepletion.

7. Subject's tumor shows positive MAGE-A10 expression

8. Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

9. Subject has a left ventricular ejection fraction =50%.

10. Subject is fit for leukapheresis and has adequate venous access for the cell collection.

11. Female subject of childbearing potential (FCBP) must have a negative urine or serum pregnancy test or male subject must be surgically sterile or agree to use a double barrier contraception method or abstain from heterosexual activity with a female of childbearing potential starting at the first dose of chemotherapy and for 4 months thereafter.

12. Subject must have adequate organ function per protocol

Exclusion Criteria:

1. Subject is HLA-A*02:05 in either allele, HLA-B*15:01 and/or HLA-B*46:01 positive. Subject has any A*02 null allele (designated with an "N", e.g. A*02:32N) as the sole HLA-A*02 allele.

2. Subject has received or plans to receive excluded therapy/treatment prior to leukapheresis or lymphodepleting chemotherapy per protocol

3. Subject that has toxicity from previous anti-cancer therapy must have recovered to = Grade 1 prior to enrollment

4. Subject has history of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study.

5. Subject had major surgery within 4 weeks prior to lymphodepletion; subjects should have been fully recovered from any surgical related toxicities.

6. Subject has an electrocardiogram (ECG) showing clinically significant abnormality at Screening or showing an average QTc interval =450 msec in males and =470 msec in females (=480 msec for subjects with bundle branch block [BBB]) over 3 consecutive ECGs. Either Fridericia's or Bazett's formula may be used to correct the QT interval.

7. Subject has symptomatic CNS metastases.

8. Subject has a history of chronic or recurrent severe autoimmune or immune mediated disease

9. Subject has any other active malignancy besides the tumor under study within 3 years prior to Screening.

10. Subject has uncontrolled intercurrent illness

11. Subject has active infection with HIV, HBV, HCV or HTLV

12. Subject is pregnant or breastfeeding.

Related Conditions & MeSH terms

• Bladder Urothelial Carcinoma
• Carcinoma
• Carcinoma, Transitional Cell
• Head and Neck Cancer
• Head and Neck Neoplasms
• Melanoma
• Urothelial Carcinoma

Intervention

Genetic:
• Autologous genetically modified MAGE A10?7?6T cells
Infusion of autologous genetically modified MAGE A10?7?6T on Day 1

Locations

Country	Name	City	State
Canada	Princess Margaret Cancer Centre	Toronto	Ontario
Spain	Hospital Universitario 12 Octubre Avda. de Córdoba	Madrid
Spain	Start Madrid-FJD, Fundación Jim?nez Díaz	Madrid
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	Roswell Park Cancer Institute	Buffalo	New York
United States	Ohio State University Wexner Medical Center	Columbus	Ohio
United States	MD Anderson Cancer Center	Houston	Texas
United States	Tennessee Oncology - Sarah Cannon Research Institute	Nashville	Tennessee
United States	Vanderbilt - Ingram Cancer Center	Nashville	Tennessee
United States	Fox Chase Cancer Center	Philadelphia	Pennsylvania
United States	Washington University - School of Medicine	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
Adaptimmune

Countries where clinical trial is conducted

United States,  Canada,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects with adverse events (AE), including serious adverse events (SAE).	Determine if treatment with autologous genetically modified T cells, (MAGE A10?7?6T ) is safe and tolerable through laboratory assessments including chemistry, hematology and coagulation; and cardiac assessments, including ECG/troponin.	3 years
Primary	Evaluation of the persistence of genetically modified T cells	Evaluation of the persistence of the infused T cells in the periphery.	3 years
Primary	Measurement of RCL in genetically modified T cells.	Evaluation of RCL in Subject PBMCs using PCR-based assay.	3 years
Primary	Assessment of dose limiting toxicities to determine optimally tolerated dose range	Evaluation of dose limiting toxicities will be performed using the CTCAE Version 4.0	3 years
Primary	Proportion of subjects with a confirmed Complete Response (CR) and/or Partial Response (PR).	Evaluation of the efficacy of the treatment by assessment of the Overall Response Rate according to RECIST v1.1	3 years
Primary	Interval between the date of first T cell infusion dose and first documented evidence of CR or PR.	Evaluation of the efficacy of the treatment by assessment of time to first response.	3 years
Primary	Interval between the date of first documented evidence of CR or PR until first documented disease progression or death due to any cause.	Evaluation of the efficacy of the treatment by assessment of duration of response.	3 years
Primary	Interval between the date of first documented evidence of SD until first documented disease progression or death due to any cause.	Evaluation of the efficacy of the treatment by assessment of duration of stable disease.	3 years
Primary	Interval between the date of first T cell infusion and the earliest date of disease progression or death due to any cause	Evaluation of the efficacy of the treatment by assessment of progression-free survival.	3 years
Primary	Interval between the date of first T cell infusion and date of death due to any cause.	Evaluation of the efficacy of the treatment by assessment of overall survival.	3 years
Primary	Number and % of subjects having any Long Term Follow Up Adverse Events (AEs)	New occurrence of any malignancy; New occurrence or exacerbation of a pre-existing neurologic disorder; New occurrence or exacerbation of a prior rheumatologic or other autoimmune disorder; New occurrence of a hematologic disorder; New occurrence of any opportunistic and/or serious infections; New occurrence of any unanticipated illness and/or hospitalization deemed related to gene modified cell therapy	15 years post last treatment (infusion)